Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®: A Retrospective Study
Condition: Relapsing-remitting Multiple SclerosisInterventions: Drug: Rebif; Drug: TecfideraSponsors: IMS HEALTH GmbH & Co. OHG; EMD SeronoRecruiting - verified June 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 3, 2016 Category: Research Source Type: clinical trials